Bimmer E. Claessen

Research Field

Bivalirudin

10.1016/j.jacc.2011.12.042

Cite

Citations (52)

Predictors of suboptimal TIMI flow after primary angioplasty for acute myocardial infarction: results from the HORIZONS-AMI trial

EuroIntervention (2013)

Adriano Caixeta Alexandra J. Lansky Roxana Mehran Sorin J. Brener Bimmer E. Claessen

The predictors of TIMI flow <3 after PCI in patients with acute myocardial infarction have not been examined in a contemporary, large-scale multicentre prospective study.The HORIZONS-AMI trial randomised 3,602 patients with STEMI undergoing primary PCI to bivalirudin (n=1,800) vs. unfractionated heparin plus a glycoprotein IIb/IIIa inhibitor (n=1,802). A total of 3,845 treated lesions (3,362 vessels) were analysed by the core lab; 2,942 vessels (87.5%) and 2,758 patients (87.1%) had final TIMI 3 flow, while 407 (12.9%) had TIMI flow <3. The independent predictors of TIMI flow <3 were age (OR 1.23 per 10-year increase; 95% CI: 1.12 to 1.35; p<0.0001), anterior MI (OR 1.65; 95% CI: 1.33 to 2.05; p<0.0001), baseline TIMI flow grade 0/1 (OR 2.79; 95% CI: 2.14 to 3.62; p<0.0001), and lesion length (OR 1.05 per 10 mm increase; 95% CI: 1.02 to 1.09; p=0.005). The three-year mortality of patients in whom final TIMI 3 flow was achieved was significantly lower than that of patients in whom TIMI 3 flow was not achieved (5.5% vs. 10.5%; p<0.0001).In this large-scale, randomised trial, failure to restore normal TIMI flow after primary PCI in STEMI occurred in 12.9% of patients, and was associated with patient-related factors (age), anatomical factors (anterior MI location), and angiographic factors (baseline TIMI 0/1 flow and lesion length). Failure to achieve TIMI 3 flow continues to be a powerful predictor of mortality after primary PCI in the contemporary era.http://www.clinicaltrials.gov. Unique identifier: NCT00433966.

TIMI

Bivalirudin

10.4244/eijv9i2a37

Cite

Citations (44)

TCT-339 Paclitaxel-Eluting Balloon vs. Everolimus-Eluting Stent in Patients with Diabetes Mellitus and In-Stent Restenosis: Insights from the Randomized DARE Trial

Journal of the American College of Cardiology (2018)

Bimmer E. Claessen José P.S. Henriques René van der Schaaf Kirsten Boerlage‐van Dijk Jeroen Vendrik

Everolimus

10.1016/j.jacc.2018.08.1486

Cite

Citations (0)

Contents

The American Journal of Cardiology (2020)

Fahad Alkhalfan Tarek Nafee Megan K. Yee Gerald Chi David Schneider

10.1016/s0002-9149(20)30028-x

Cite

Citations (0)

Myocardium at risk in chronic total coronary occlusion territory collateralized by an infarct-related artery: The double jeopardy theory

IJC Heart & Vasculature (2025)

Yvemarie Somsen Roel Hoek Ruben W. de Winter Rocco Giunta Stefan Schumacher

Double jeopardy

Coronary occlusion

Collateralized debt obligation

Coronary artery occlusion

10.1016/j.ijcha.2025.101631

Cite

Citations (0)

IMPACT OF GENDER IN HIGH BLEEDING RISK PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION WITH XIENCE EVEROLIMUS ELUTING STENT: A PATIENT-LEVEL POOLED ANALYSIS FROM FOUR XIENCE POST-APPROVAL TRIALS

Journal of the American College of Cardiology (2019)

Rishi Chandiramani Paul Guedeney Bimmer E. Claessen Marco Valgimigli Roxana Mehran

Pooled analysis

Everolimus

10.1016/s0735-1097(19)31872-8

Cite

Citations (0)

Cangrelor Use in Routine Practice: A Two-Center Experience

Journal of Clinical Medicine (2021)

N M R Van Der Sangen Ho Yee Cheung Niels Verouden Yolande Appelman Marcel A.M. Beijk

Cangrelor is the first and only intravenous P2Y

Cangrelor

Center (category theory)

10.3390/jcm10132829

Cite

Citations (3)

Analysis of biomarkers for risk of acute kidney injury after primary angioplasty for acute ST‐segment elevation myocardial infarction: Results of the HORIZONS‐AMI trial

Catheterization and Cardiovascular Interventions (2014)

Alejandra Guerchicoff Gregg W. Stone Roxana Mehran Ke Xu Dru J. Nichols

Contrast-induced acute kidney injury (CI-AKI) may occur after percutaneous coronary intervention (PCI).We evaluated patients with ST-elevation myocardial infarction (STEMI) undergoing emergency PCI with serial biomarkers.Of the 390 patients enrolled in the HORIZONS-AMI biomarker substudy, 56 (14.3%) developed AKI. In the AKI group, the levels of B-type natriuretic peptide were consistently higher than in the no-AKI group at baseline (P = 0.0327), hospital discharge (P = 0.0002), 30-day follow-up (P = 0.0193), and 1-year follow-up (P = 0.031). At hospital discharge, the AKI group had elevated biomarkers compared to the no-AKI group: D-dimer (P = 0.0066), C-reactive protein (P = 0.0468), endothelial cell-selective adhesion molecule (P = 0.0169), adiponectin (P = 0.0346), and von Willebrand factor (P = 0.0168); there was also a trend toward higher cystatin C (P = 0.0585) in the AKI group. Similar correlations between biomarker panel increase and the development of CI-AKI were consistent at baseline, 30-day, and 1-year follow-up. Chemokine (C-C motif) ligand 23 showed an opposite pattern with an increase at all time points in the no-AKI compared to the AKI group.The risk of CI-AKI after primary PCI for STEMI may be associated with hemostatic imbalances, activation of procoagulants, decreased endogenous anticoagulants, enhanced inflammation, platelet activation, or decreased fibrinolytic activity.

10.1002/ccd.25620

Cite

Citations (24)

IMPACT OF ASPIRIN DOSE ON LONG TERM CLINICAL OUTCOMES AFTER STENTING FOR ACUTE MYOCARDIAL INFARCTION: 3-YEAR FOLLOW-UP DATA FROM THE HORIZONS-AMI TRIAL

Journal of the American College of Cardiology (2011)

Jason C. Kovacic Roxana Mehran George Dangas Bimmer E. Claessen Helen Parise

Coronary stenting

10.1016/s0735-1097(11)61633-1

Cite

Citations (0)

TCT-4 Rationale and Design of the IMODERN STOP-IMH Randomized Trial: The Safety of Ticagrelor Monotherapy After Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction and the Effect on Intramyocardial Hemorrhage

Journal of the American College of Cardiology (2024)